• Something wrong with this record ?

Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data

V. Sandecka, L. Pour, I. Špička, J. Minařík, J. Radocha, T. Jelínek, P. Pavlíček, A. Jungová, P. Kessler, M. Wróbel, M. Štork, J. Štraub, T. Pika, L. Čápková, S. Ševčíková, V. Maisnar, R. Hájek

. 2022 ; 69 (6) : 1474-1479. [pub] -

Language English Country Slovakia

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23004919

We assessed the outcomes of pomalidomide and dexamethasone treatment in relapsed/refractory multiple myeloma (RRMM) patients with ≥1 prior line of therapy. We analyzed the data of all RRMM patients treated with pomalidomide and dexamethasone at nine Czech centers between 2013 and 2018. The source of the data was the Registry of Monoclonal Gammopathies of the Czech Republic. Primary endpoints included response rates based on International Myeloma Working Group criteria and survival measures, including progression-free survival (PFS) and overall survival (OS). Secondary endpoints were toxicities and previous treatment patterns, including refractory to lenalidomide, and their impact on final outcomes. The overall response rate was 51.8% and the clinical benefit rate (including patients with minimal response) was 67.1%, with 0.6% of complete responses, 8.5% of very good partial responses, and 42.1% of partial responses (PR). Overall, 16.5% of patients had a minimal response, and 32.3% had stable disease /progression. Median PFS was 8.8 months and the median OS was 14.2 months. In patients who achieved ≥PR, the median PFS and OS were significantly longer compared to non-responders (median PFS (12.1 vs. 4.5 months, p≤0.001 respectively), median OS (22.1 vs. 7.7 months, p≤0.001, respectively). The most frequent adverse events (AEs) were neutropenia (29.9%) and anemia (18.9%), non-hematological AEs included infections (14.6%) and fatigue (7.3%). Our analysis confirmed the effectiveness of pomalidomide and dexamethasone in a real-world setting. This therapy achieved reasonable outcomes comparable to the data from clinical trials even though this was an unbiased cohort of patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004919
003      
CZ-PrNML
005      
20230714085021.0
007      
ta
008      
230418s2022 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2022_220813N827 $2 doi
035    __
$a (PubMed)36591805
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Sandecka, Viera $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data / $c V. Sandecka, L. Pour, I. Špička, J. Minařík, J. Radocha, T. Jelínek, P. Pavlíček, A. Jungová, P. Kessler, M. Wróbel, M. Štork, J. Štraub, T. Pika, L. Čápková, S. Ševčíková, V. Maisnar, R. Hájek
520    9_
$a We assessed the outcomes of pomalidomide and dexamethasone treatment in relapsed/refractory multiple myeloma (RRMM) patients with ≥1 prior line of therapy. We analyzed the data of all RRMM patients treated with pomalidomide and dexamethasone at nine Czech centers between 2013 and 2018. The source of the data was the Registry of Monoclonal Gammopathies of the Czech Republic. Primary endpoints included response rates based on International Myeloma Working Group criteria and survival measures, including progression-free survival (PFS) and overall survival (OS). Secondary endpoints were toxicities and previous treatment patterns, including refractory to lenalidomide, and their impact on final outcomes. The overall response rate was 51.8% and the clinical benefit rate (including patients with minimal response) was 67.1%, with 0.6% of complete responses, 8.5% of very good partial responses, and 42.1% of partial responses (PR). Overall, 16.5% of patients had a minimal response, and 32.3% had stable disease /progression. Median PFS was 8.8 months and the median OS was 14.2 months. In patients who achieved ≥PR, the median PFS and OS were significantly longer compared to non-responders (median PFS (12.1 vs. 4.5 months, p≤0.001 respectively), median OS (22.1 vs. 7.7 months, p≤0.001, respectively). The most frequent adverse events (AEs) were neutropenia (29.9%) and anemia (18.9%), non-hematological AEs included infections (14.6%) and fatigue (7.3%). Our analysis confirmed the effectiveness of pomalidomide and dexamethasone in a real-world setting. This therapy achieved reasonable outcomes comparable to the data from clinical trials even though this was an unbiased cohort of patients.
650    _2
$a lidé $7 D006801
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    12
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a rutinně sbírané zdravotní údaje $7 D000085143
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pour, Luděk $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Špička, Ivan $u 1st Department of Medicine-Department of Hematology, First Faculty of Medicine, Charles University and General Hospital,, Prague, Czech Republic
700    1_
$a Minařík, Jiří $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Radocha, Jakub $u 4th Department of Internal Medicine-Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
700    1_
$a Jelínek, Tomáš $u Department of Hematooncology, University Hospital, Ostrava, Czech Republic $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Pavlíček, Petr $u Department of Internal Medicine and Hematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Jungová, Alexandra $u Hematology and Oncology Department, Charles University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Kessler, Petr $u Department of Hematology and Transfusion Medicine, Hospital Pelhrimov, Pelhrimov, Czech Republic
700    1_
$a Wróbel, Marek $u Department of Clinical Hematology, Hospital Novy Jicin, Novy Jicin, Czech Republic $7 xx0303976
700    1_
$a Štork, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Štraub, Jan $u 1st Department of Medicine-Department of Hematology, First Faculty of Medicine, Charles University and General Hospital,, Prague, Czech Republic
700    1_
$a Pika, Tomáš $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Čápková, Lenka $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Ševčíková, Sabina $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Maisnar, Vladimír $u 4th Department of Internal Medicine-Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
700    1_
$a Hájek, Roman $u Department of Hematooncology, University Hospital, Ostrava, Czech Republic $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 69, č. 6 (2022), s. 1474-1479
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36591805 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230714085021 $b ABA008
999    __
$a ok $b bmc $g 1925171 $s 1191128
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 69 $c 6 $d 1474-1479 $e - $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options